Compare · BBNX vs BDX
BBNX vs BDX
Side-by-side comparison of Beta Bionics Inc. (BBNX) and Becton Dickinson and Company (BDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBNX and BDX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.64B, about 93.3x BBNX ($467.9M).
- Over the past year, BBNX is down 29.8% and BDX is down 8.7% - BDX leads by 21.1 points.
- BDX has been more active in the news (15 items in the past 4 weeks vs 4 for BBNX).
- BDX has more recent analyst coverage (25 ratings vs 16 for BBNX).
- Company
- Beta Bionics Inc.
- Becton Dickinson and Company
- Price
- $10.49-0.80%
- $153.22+5.93%
- Market cap
- $467.9M
- $43.64B
- 1M return
- +7.04%
- -2.48%
- 1Y return
- -29.79%
- -8.68%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 15
- Recent ratings
- 16
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BBNX
- Beta Bionics to Present at the Bank of America Securities Health Care Conference
- SEC Form 10-Q filed by Beta Bionics Inc.
- Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
- SEC Form DEFA14A filed by Beta Bionics Inc.
- SEC Form DEF 14A filed by Beta Bionics Inc.
- Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
- Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
- Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
Latest BDX
- SEC Form S-8 filed by Becton Dickinson and Company
- SEC Form S-8 filed by Becton Dickinson and Company
- SEC Form 10-Q filed by Becton Dickinson and Company
- Amendment: Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD Appoints Vitor Roque Chief Financial Officer
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Second Quarter Fiscal 2026 Financial Results
- Evercore ISI resumed coverage on Becton Dickinson with a new price target
- BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits